Oakley Gerard J, Tubbs Raymond R, Crowe Joseph, Sebek Bruce, Budd G Thomas, Patrick Rebecca J, Procop Gary W
Marshall University School of Medicine, Huntington, WV, USA.
Am J Clin Pathol. 2006 Jul;126(1):55-8. doi: 10.1309/E0YE-KHBP-3YYQ-YUBD.
The prognostic and therapeutic implications of HER-2 gene amplification and estrogen and progesterone receptor status in breast cancer are well described. To address the relative paucity of information concerning HER-2 amplification for tubular carcinomas, we assessed the frequency of gene amplification in 55 tubular carcinomas of the breast from 54 patients, 5 of which had axillary node metastases. The HER-2 gene copy number was assessed by fluorescence in situ hybridization for the majority of tumors analyzed, whereas estrogen and progesterone receptor status was achieved by immunohistochemical analysis. HER-2 gene amplification was not observed in any of the tumors examined, and most were estrogen receptor-positive. This HER-2 gene amplification frequency was significantly lower than the frequency of gene amplification previously reported for all invasive ductal carcinoma of no special type (P < .01). HER-2 gene amplification likely occurs infrequently, or not at all, in tubular carcinomas of the breast, whereas most express estrogen receptors.
HER-2基因扩增以及雌激素和孕激素受体状态在乳腺癌中的预后和治疗意义已有详尽描述。为了解有关乳腺小管癌HER-2扩增的信息相对较少的情况，我们评估了54例患者的55例乳腺小管癌的基因扩增频率，其中5例有腋窝淋巴结转移。对于大多数分析的肿瘤，通过荧光原位杂交评估HER-2基因拷贝数，而雌激素和孕激素受体状态则通过免疫组化分析确定。在所检查的任何肿瘤中均未观察到HER-2基因扩增，并且大多数为雌激素受体阳性。这种HER-2基因扩增频率显著低于先前报道的所有非特殊类型浸润性导管癌的基因扩增频率（P <.01）。HER-2基因扩增在乳腺小管癌中可能很少发生，或根本不发生，而大多数表达雌激素受体。
